<!DOCTYPE html>
<html>
<head>
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="color-scheme" content="light dark">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-dark-5@1.1.3/dist/css/bootstrap-dark.min.css" integrity="sha384-pZAJcuaxKZEGkzXV5bYqUcSwBfMZPdQS/+JXdYOu9ScyZJMnGHD5Xi6HVHfZuULH" crossorigin="anonymous">
    <script defer data-domain="wa-law.org" src="https://plausible.io/js/plausible.js"></script>

    <title>Engrossed Substitute House Bill 1689 as Recommended by Health Care & Wellness</title>
</head>
<body>
<div class="container-sm">
<h1 id="engrossed-substitute-house-bill-1689-as-recommended-by-health-care--wellness-1">Engrossed Substitute House Bill 1689 as Recommended by Health Care &amp; Wellness <a class="header-anchor" href="#engrossed-substitute-house-bill-1689-as-recommended-by-health-care--wellness-1">¶</a></h1>
<p><a href="http://lawfilesext.leg.wa.gov/biennium/2021-22/Pdf/Bills/House%20Bills/1689-S.E.pdf">Source</a></p>
<h2 id="section-1-2227">Section 1 <a class="header-anchor" href="#section-1-2227">¶</a></h2>
<blockquote>
<p>This section adds a new section to an existing chapter <a href="/rcw/48_insurance/48.043_insurance_reform.html">48.43</a>. Here is the <a href="rcw/48_insurance/48.043_insurance_reform.html">modified chapter</a> for context.</p>
</blockquote>
<ol>
<li>
<p>Health plans issued or renewed on or after January 1, 2023, shall exempt an enrollee from prior authorization requirements for coverage of biomarker testing for either of the following:</p>
<ol type="a">
<li>
<p>Stage 3 or 4 cancer; or</p>
</li>
<li>
<p>Recurrent, relapsed, refractory, or metastatic cancer.</p>
</li>
</ol>
</li>
<li>
<p>For purposes of this section, &quot;biomarker test&quot; means a single or multigene diagnostic test of the cancer patient's biospecimen, such as tissue, blood, or other bodily fluids, for DNA, RNA, or protein alterations, including phenotypic characteristics of a malignancy, to identify an individual with a subtype of cancer, in order to guide patient treatment.</p>
</li>
<li>
<p>For purposes of this section, biomarker testing must be:</p>
<ol type="a">
<li>
<p>Recommended in the latest version of nationally recognized guidelines or biomarker compendia, such as those published by the national comprehensive cancer network;</p>
</li>
<li>
<p>Approved by the United States food and drug administration or a validated clinical laboratory test performed in a clinical laboratory certified under the clinical laboratory improvement amendments or in an alternative laboratory program approved by the centers for medicare and medicaid services;</p>
</li>
<li>
<p>A covered service; and</p>
</li>
<li>
<p>Prescribed by an in-network provider.</p>
</li>
</ol>
</li>
<li>
<p>This section does not limit, prohibit, or modify an enrollee's rights to biomarker testing as part of an approved clinical trial under chapter 69.77 RCW.</p>
</li>
<li>
<p>Nothing in this section may be construed to mandate coverage of a health care service.</p>
</li>
<li>
<p>Nothing in this section prohibits a health plan from requiring a biomarker test prior to approving a drug or treatment.</p>
</li>
<li>
<p>This section does not limit an enrollee's rights to access individual gene tests.</p>
</li>
</ol>
<h2 id="section-2-1777">Section 2 <a class="header-anchor" href="#section-2-1777">¶</a></h2>
<blockquote>
<p>This section adds a new section to an existing chapter <a href="/rcw/74_public_assistance/74.09_medical_care.html">74.09</a>. Here is the <a href="rcw/74_public_assistance/74.09_medical_care.html">modified chapter</a> for context.</p>
</blockquote>
<ol>
<li>
<p>Upon initiation or renewal of a contract with the authority to administer a medicaid managed care plan, a managed care organization shall exempt an enrollee from prior authorization requirements for coverage of biomarker testing for either of the following:</p>
<ol type="a">
<li>
<p>Stage 3 or 4 cancer; or</p>
</li>
<li>
<p>Recurrent, relapsed, refractory, or metastatic cancer.</p>
</li>
</ol>
</li>
<li>
<p>For purposes of this section, &quot;biomarker test&quot; means a single or multigene diagnostic test of the cancer patient's biospecimen, such as tissue, blood, or other bodily fluids, for DNA, RNA, or protein alterations, including phenotypic characteristics of a malignancy, to identify an individual with a subtype of cancer, in order to guide patient treatment.</p>
</li>
<li>
<p>For purposes of this section, biomarker testing must be:</p>
<ol type="a">
<li>
<p>Recommended in the latest version of nationally recognized guidelines or biomarker compendia, such as those published by the national comprehensive cancer network;</p>
</li>
<li>
<p>Approved by the United States food and drug administration or a validated clinical laboratory test performed in a clinical laboratory certified under the clinical laboratory improvement amendments or in an alternative laboratory program approved by the centers for medicare and medicaid services;</p>
</li>
<li>
<p>A covered service; and</p>
</li>
<li>
<p>Prescribed by an in-network provider.</p>
</li>
</ol>
</li>
<li>
<p>This section does not limit, prohibit, or modify an enrollee's rights to biomarker testing as part of an approved clinical trial under chapter 69.77 RCW.</p>
</li>
<li>
<p>Nothing in this section may be construed to mandate coverage of a health care service.</p>
</li>
<li>
<p>Nothing in this section prohibits a managed care plan from requiring a biomarker test prior to approving a drug or treatment.</p>
</li>
<li>
<p>This section does not limit an enrollee's rights to access individual gene tests.</p>
</li>
</ol>

<hr/>
Created by @tannewt. Contribute <a href="https://github.com/tannewt/wa-law.org">on GitHub</a>.
</div>
<script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.0/dist/js/bootstrap.bundle.min.js" integrity="sha384-U1DAWAznBHeqEIlVSCgzq+c9gqGAJn5c/t99JyeKa9xxaYpSvHU5awsuZVVFIhvj" crossorigin="anonymous"></script>
</body>
</html>